| 製品名 | Cetilistat |
|---|---|
| CAS番号 | 282526-98-1 |
| 分子式 | C26H33NO3 |
| 分子量 | 407.55 |
| 外観 | 白色からオフホワイトの結晶性粉末 |
| 仕様 | 99% (HPLC) |
| 分析(HPLC) | ≥99% |
| 乾燥減量 | ≤0.5% |
| 重金属 | 10 ppm以下 |
| 仕様 | 99% |
お困りですか? 弊社チームまでお問い合わせください

Cetilistat (CAS 282526-98-1) is a novel lipase inhibitor designed for the management of obesity. Unlike orlistat, which is a saturated derivative, cetilistat features a benzoxazinone core that offers improved gastrointestinal tolerability. It works by irreversibly inhibiting pancreatic and gastric lipases, thereby reducing dietary fat absorption by approximately 30% at therapeutic doses. We supply this API in high purity (≥99% by HPLC) as a white to off-white crystalline powder, suitable for oral solid dosage forms and clinical research.
As a second-generation lipase inhibitor, cetilistat has undergone Phase III trials for obesity and type 2 diabetes, showing comparable efficacy to orlistat with fewer steatorrhea side effects. Its chemical name is 2-(2,4-difluorophenyl)-6-(2-{2-[2-(2,2-dimethylpropyl)phenoxy]ethoxy}ethyl)-4,5-dihydro-1,3-oxazin-4-one, and it is also known by the code ATL-962. This product is intended for pharmaceutical formulation development and research purposes only.
同義語: 2-(2,4-Difluorophenyl)-6-(2-{2-[2-(2,2-dimethylpropyl)phenoxy]ethoxy}ethyl)-4,5-dihydro-1,3-oxazin-4-one, ATL-962, Cetilistat (USAN), 2H-1,3-Oxazin-4-one, 2-(2,4-difluorophenyl)-6-(2-(2-(2-(2,2-dimethylpropyl)phenoxy)ethoxy)ethyl)-4,5-dihydro-
Every batch is tested for assay (HPLC ≥99%), loss on drying (≤0.5%), and heavy metals (≤10 ppm). Full COA, MSDS, and TDS are provided with each shipment. Stability data under ICH conditions is available upon request to support your formulation development and regulatory filings.
Standard packaging: 100 g, 500 g, and 1 kg. Custom packing sizes are available. In-stock items ship within 3-5 business days; MOQ is 100 g. For pricing, samples, or bulk orders, contact our sales team.